Nimesulide is well-tolerated as an alternative to nonsteroidal antiinflammatory drugs (NSAIDs) in patients with a previous adverse reaction to other classes of NSAIDs. However, there is little information in the literature about its long-term tolerability. The study was carried out on 625 patients who had experienced adverse reactions to one or more NSAIDs. All patients received and tolerated peroral challenges with nimesulide. On the first day, patients were given an equivalent number of placebo doses to the planned number of nimesulide doses. In a successive session, the test was administered by means of increasing doses of nimesulide at 30 min intervals until the common daily therapeutic dose of 100 mg was reached (10 mg-20 mg-30 mg-40 mg). A questionnaire was distributed to all subjects. In particular, they were asked to clarify any reactive symptoms they had developed after ingestion of the drug. It was found that only 2.1% (4/192) of subjects who were given this drug experienced urticaria during treatment. We have identified three significant risk factors: a history of chronic urticaria, a history of antibiotic hypersensitivity and a history of hypersensitivity to more than one class of NSAIDs. In patients with the above risk factors, a prior tolerance test with a selective COX2 antagonist should be administered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1081/iph-200026916 | DOI Listing |
Cureus
December 2024
Emergency Medicine, Hospital Episcopal San Lucas, Ponce, PRI.
Sciatica, often characterized by low back pain (LBP) radiating to the leg, is a challenging condition to manage, especially when conventional therapies fail. We present the case of a 27-year-old man who suffered from persistent low back pain with left-sided radicular symptoms. Despite treatment with numerous oral medications, including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentinoids, and muscle relaxants, his symptoms persisted and intensified.
View Article and Find Full Text PDFCureus
December 2024
Department of Surgery, Itoigawa General Hospital, Itoigawa, JPN.
Objective This study aimed to investigate prescription patterns for migraine patients aged 18 years and older using the REZULT database, managed by Japan System Techniques Co., Ltd. in Tokyo, Japan.
View Article and Find Full Text PDFAm J Otolaryngol
January 2025
Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Via Consolare Valeria 1, 98125 3, Italy. Electronic address:
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.
View Article and Find Full Text PDFHand Surg Rehabil
January 2025
Orthopedic Surgery Department, CHU Caremeauux,Debré, Nîmes, France.
Purpose: This study aimed to evaluate the outcomes of a novel antegrade, ultrasound-guided release of the first extensor tendon compartment for treating De Quervain's disease.
Methods: We conducted a retrospective, single-center study of 34 patients who underwent ultrasound-guided release of the first extensor compartment for clinically diagnosed De Quervain's disease between June 2022 and December 2023. Inclusion criteria included age >18 years and failure of conservative treatment (e.
Int J Cardiol
January 2025
Cardiology and Cardiothoracic Department, University Hospital "Santa Maria della Misericordia" (ASUFC) Udine, Italy.
Background: Patients with pericarditis may show elevation of C-reactive protein (CRP) and pericardial effusion at presentation. There are limited data on the prognostic implications of this inflammatory phenotype.
Objectives: Aim of the present study is to evaluate the outcome of the inflammatory phenotype in a cohort of patients with acute pericarditis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!